These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 26726958)

  • 1. Vascular endothelial growth factor: Potential predictor of treatment response in major depression.
    Clark-Raymond A; Meresh E; Hoppensteadt D; Fareed J; Sinacore J; Garlenski B; Halaris A
    World J Biol Psychiatry; 2017 Dec; 18(8):575-585. PubMed ID: 26726958
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vascular Endothelial Growth Factor: a potential diagnostic biomarker for major depression.
    Clark-Raymond A; Meresh E; Hoppensteadt D; Fareed J; Sinacore J; Halaris A
    J Psychiatr Res; 2014 Dec; 59():22-7. PubMed ID: 25193461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients.
    Yevtushenko VY; Belous AI; Yevtushenko YG; Gusinin SE; Buzik OJ; Agibalova TV
    Clin Ther; 2007 Nov; 29(11):2319-32. PubMed ID: 18158074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neurotrophic factors in depression in response to treatment.
    Buttenschøn HN; Foldager L; Elfving B; Poulsen PH; Uher R; Mors O
    J Affect Disord; 2015 Sep; 183():287-94. PubMed ID: 26047306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peripheral vascular endothelial growth factor level is associated with antidepressant treatment response: results of a preliminary study.
    Halmai Z; Dome P; Dobos J; Gonda X; Szekely A; Sasvari-Szekely M; Faludi G; Lazary J
    J Affect Disord; 2013 Jan; 144(3):269-73. PubMed ID: 23021824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An investigation of cortical thickness and antidepressant response in major depressive disorder: A CAN-BIND study report.
    Suh JS; Minuzzi L; Raamana PR; Davis A; Hall GB; Harris J; Hassel S; Zamyadi M; Arnott SR; Alders GL; Sassi RB; Milev R; Lam RW; MacQueen GM; Strother SC; Kennedy SH; Frey BN
    Neuroimage Clin; 2020; 25():102178. PubMed ID: 32036277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact on cortisol and antidepressant efficacy of quetiapine and escitalopram in depression.
    Sarubin N; Nothdurfter C; Schmotz C; Wimmer AM; Trummer J; Lieb M; Uhr M; Baghai TC; Wetter TC; Bühner M; Rupprecht R; Schüle C
    Psychoneuroendocrinology; 2014 Jan; 39():141-151. PubMed ID: 24275013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quetiapine as combination treatment with citalopram in unipolar depression with prominent somatic symptoms: a randomised, double-blind, placebo-controlled pilot study.
    Quante A; Regen F; Schindler F; Volkmer K; Severus E; Urbanek C; Luborzewski A; Roepke S; Anghelescu I
    Psychiatr Danub; 2013 Sep; 25(3):214-20. PubMed ID: 24048387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced serum VGF levels were reversed by antidepressant treatment in depressed patients.
    Jiang H; Chen S; Lu N; Yue Y; Yin Y; Zhang Y; Jiang W; Liang J; Yuan Y
    World J Biol Psychiatry; 2017 Dec; 18(8):586-591. PubMed ID: 28635540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of escitalopram/quetiapine combination therapy versus escitalopram monotherapy on hypothalamic-pituitary-adrenal-axis activity in relation to antidepressant effectiveness.
    Nothdurfter C; Schmotz C; Sarubin N; Baghai TC; Laenger A; Lieb M; Bondy B; Rupprecht R; Schüle C
    J Psychiatr Res; 2014 May; 52():15-20. PubMed ID: 24513501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of potentially predictive factors of efficacy of adjunct extended-release quetiapine fumarate in patients with major depressive disorder.
    Bauer M; Thase ME; Liu S; Earley W; Eriksson H
    J Psychopharmacol; 2015 May; 29(5):565-74. PubMed ID: 25257148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapid antidepressant changes with sleep deprivation in major depressive disorder are associated with changes in vascular endothelial growth factor (VEGF): a pilot study.
    Ibrahim L; Duncan W; Luckenbaugh DA; Yuan P; Machado-Vieira R; Zarate CA
    Brain Res Bull; 2011 Aug; 86(1-2):129-33. PubMed ID: 21704134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. VEGF serum levels in depressed patients during SSRI antidepressant treatment.
    Ventriglia M; Zanardini R; Pedrini L; Placentino A; Nielsen MG; Gennarelli M; Bocchio-Chiavetto L
    Prog Neuropsychopharmacol Biol Psychiatry; 2009 Feb; 33(1):146-9. PubMed ID: 19059450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peripheral vascular endothelial growth factor changes after transcranial magnetic stimulation in treatment-resistant depression.
    Fukuda AM; Hindley LE; Kang JWD; Tirrell E; Tyrka AR; Ayala A; Carpenter LL
    Neuroreport; 2020 Nov; 31(16):1121-1127. PubMed ID: 32956213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intrinsic connectomes are a predictive biomarker of remission in major depressive disorder.
    Korgaonkar MS; Goldstein-Piekarski AN; Fornito A; Williams LM
    Mol Psychiatry; 2020 Jul; 25(7):1537-1549. PubMed ID: 31695168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Vascular endothelial growth factor (VEGF) as a potential biomarker in major depressive disorder].
    Elemery M; Kiss S; Gonda X; Dome P; Lazary J
    Neuropsychopharmacol Hung; 2017 Dec; 19(4):183-188. PubMed ID: 29411705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative electroencephalogram biomarkers for predicting likelihood and speed of achieving sustained remission in major depression: a report from the biomarkers for rapid identification of treatment effectiveness in major depression (BRITE-MD) trial.
    Cook IA; Hunter AM; Gilmer WS; Iosifescu DV; Zisook S; Burgoyne KS; Howland RH; Trivedi MH; Jain R; Greenwald S; Leuchter AF
    J Clin Psychiatry; 2013 Jan; 74(1):51-6. PubMed ID: 23419226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single i.v. ketamine augmentation of newly initiated escitalopram for major depression: results from a randomized, placebo-controlled 4-week study.
    Hu YD; Xiang YT; Fang JX; Zu S; Sha S; Shi H; Ungvari GS; Correll CU; Chiu HF; Xue Y; Tian TF; Wu AS; Ma X; Wang G
    Psychol Med; 2016 Feb; 46(3):623-35. PubMed ID: 26478208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early change in reward and punishment sensitivity as a predictor of response to antidepressant treatment for major depressive disorder: a CAN-BIND-1 report.
    Allen TA; Lam RW; Milev R; Rizvi SJ; Frey BN; MacQueen GM; Müller DJ; Uher R; Kennedy SH; Quilty LC
    Psychol Med; 2019 Jul; 49(10):1629-1638. PubMed ID: 30220263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. VEGF plasma level variations in duloxetine-treated patients with major depression.
    Fornaro M; Rocchi G; Escelsior A; Contini P; Ghio M; Colicchio S; De Berardis D; Amore M; Fornaro P; Martino M
    J Affect Disord; 2013 Nov; 151(2):590-595. PubMed ID: 23871390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.